TABLE 2.
Characteristics of the sample (total n = 35).
| Intervention n = 19 | Control n = 16 | p‐value | ||
|---|---|---|---|---|
| Current age | Mean ± SD | 56.3 ± 9.3 | 59.1 ± 6.8 | 0.622 |
| Race | Black | 8 (42.1%) | 8 (50%) | 0.774 |
| White | 11 (57.9%) | 8 (50%) | ||
| Highest education | Mean ± SD | 15.2 ± 1.9 | 16.5 ± 2.0 | 0.053 |
| Marital status | Since/divorced/widowed | 8 (42.1%) | 4 (25.0%) | 0.238 |
| Married/partnered | 11 (57.9%) | 12 (75.0%) | ||
| Stage of breast cancer | Stage I | 5 (26.3%) | 4 (25.0%) | 0.858 |
| Stage II | 9 (47.4%) | 9 (56.3%) | ||
| Stage III | 4 (21.1%) | 2 (12.5%) | ||
| Unsure | 1 (5.3%) | 1 (6.2%) | ||
| Months since cancer diagnosis | Mean ± SD | 63.7 ± 53.9 | 85.9 ± 64.6 | 0.275 |
| Surgery (lumpectomy) | Yes | 16 (84.2%) | 15 (93.8%) | 0.328 |
| No | 3 (15.8%) | 1 (6.2%) | ||
| Radiation | Yes | 17 (89.5%) | 12 (75.0%) | 0.275 |
| No | 2 (10.5%) | 4 (25.0%) | ||
| Tamoxifen use | Yes | 11 (57.9%) | 5 (31.2%) | 0.084 |
| No | 8 (42.1%) | 11 (68.8%) | ||
| Aromatase inhibitor use | Yes | 8 (42.1%) | 9 (56.3%) | 0.892 |
| No | 11 (57.9%) | 7 (43.7%) | ||
Note: Race: participants identified as Black or White only so other races not listed. Surgery: yes = had surgery; no = never had breast cancer surgery. Radiation: yes = had radiation; no = never had radiation therapy. Tamoxifen use: yes = indicates current and/or past use of tamoxifen; no = never had tamoxifen. Aromatase inhibitor use: yes = indicates current and/or past use of aromatase Inhibitor; no = never had aromatase inhibitor.